Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. As an investigational compound the safety and efficacy profile of everolimus has not yet been established in all countries in pancreatic or any other type of NET, or in locally-advanced or metastatic breast cancer. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for pancreatic or any other type of NET, locally-advanced or metastatic breast cancer or additional indications anywhere else in the world.

Important Safety Information about AFINITOR (everolimus) tablets Patients should not take AFINITOR if they are allergic to AFINITOR or to any of its ingredients. Patients should tell their healthcare provider before taking AFINITOR if they are allergic to sirolimus (Rapamune®#) or temsirolimus (Torisel®#).

AFINITOR can cause serious side effects including lung or breathing problems, infections and kidney failure, which can lead to death. If patients experience these serious side effects, they may need to stop taking AFINITOR for a while or use a lower dose. Patients should tell their healthcare provider right away if they have any of these symptoms: new or worsening cough, shortness of breath, chest pain, difficulty breathin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
(Date:11/27/2014)... knows, Cyber Monday is a crazy shopping day. Owing to ... now providing many big promotions on its website. Customers can ... current prices. The discount are up to 80% off. So ... orders above $88) from Dec. 1 – 4 2014. , ... are willing to shop on the internet. As a leading ...
(Date:11/27/2014)... 28, 2014 This is a professional ... global Bronchoscopes industry with a focus on the Chinese ... status of the Bronchoscopes manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:11/27/2014)... November 27, 2014 Absolute PhysioCare ... recently announced that its personalized treatment plans, highly ... can help victims of sports injuries reach pre-injury ... or patellofemoral pain syndrome, Absolute Physio has the ... jumper’s knee, ACL tears, meniscal injuries, groin strain ...
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
Breaking Medicine News(10 mins):Health News:Tidebuy.com Launching Overcoats Sales for the Special Monday in 2014 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:Coquitlam Physiotherapy Clinic Now Helps Clients Reach Pre-Injury State 2Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... 12 (HealthDay News) -- There could be 18 million more ... over the next 40 years if smoking rates stay at ... a bacterial infection of the lungs. Smoking raises the risk ... lead author Dr. Sanjay Basu of the University of California, ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Scientists announced Wednesday ... of the naked mole rat, an exceptionally long-lived and cancer-resistant ... scientists say the findings could provide insights into human aging ... the genetic adaptations, we may be able to find treatments ...
... resected stage II and stage III colon cancer experienced ... similar recurrence-free intervals, according to a study published Oct. ... Institute. Colorectal cancer is a leading cause ... there were an estimated 146,970 new cases of colorectal ...
... the number of possible decisions that an individual cell ... and surprisingly, it,s only two. The first-of-its-kind ... inner workings of the cell decision-making process into a ... be compared with the computing power of machines. ...
... findings reported in the October 2011 issue of ... youth in health outcomes and educational equity. The ... by the American Educational Research Association (AERA). ... and Dorothy L Espelage, who conducted the research, ...
... 12 (HealthDay News) -- Exercise can prevent migraines just ... study from Sweden suggests. "Our conclusion is that ... [the migraine drug] topiramate when it comes to preventing ... unwilling or unable to take preventative medicines," study lead ...
Cached Medicine News:Health News:Rising Global Smoking Rates Could Add Millions of TB Deaths 2Health News:Genome of Cancer-Free Rodent May Give Clues to Human Aging, Disease 2Health News:Survival disparities in African-American and white colo-rectal cancer patients 2Health News:Why many cells are better than one 2Health News:Why many cells are better than one 3Health News:Education research shows LGBTQ-identified students at higher risk than straight-identified students 2Health News:Regular Exercise Seems to Guard Against Migraine 2
... System is a sterile, pre-shaped, three-dimensional device ... a mesh cylinder to a circular underlay ... unique and innovative design combines the three ... in the repair of inguinal hernias. ,Its ...
... The 800 Series KTP/YAG Surgical Laser ... market. It is a high-power, dual-wavelength ... plastic surgery, orthopedics, general surgery, neurosurgery, ... KTP/532 beam surgically cuts, vaporizes and ...
... a new, portable, light weight, high power ... cosmetic and plastic surgery, general surgery, ENT ... resurfacing, it is the smallest, yet among ... market. It provides an ideal treatment for ...
... Venus-i™ Laser System is a new, portable, ... with applications in dermatology, cosmetic and plastic ... ideal laser for skin resurfacing, it is ... Erbium:YAG lasers on the market. It provides ...
Medicine Products: